Fortress Biotech, Inc.(FBIO)Earnings, Financials & Key Ratios
FBIO•NASDAQ
$2.55
$71M mkt cap·Price updated May 6, 2026
AboutFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.Show more
- Revenue$58M-31.8%
- EBITDA-$106M+22.3%
- Net Income-$46M+24.1%
- EPS (Diluted)-2.69+68.2%
- Gross Margin63.8%-12.5%
- EBITDA Margin-183.64%-13.8%
- Operating Margin-191.38%-13.6%
- Net Margin-79.75%-11.2%
- ROIC-629.42%+75.4%
- Interest Coverage-11.12+2.2%
FBIO Key Insights
Fortress Biotech, Inc. (FBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FBIO Price & Volume
Fortress Biotech, Inc. (FBIO) stock price & volume — 10-year historical chart
Loading chart...
FBIO Growth Metrics
Fortress Biotech, Inc. (FBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years9.5%
3 Years-5.71%
TTM-0.32%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM108.22%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM92.18%
Return on Capital
10 Years-79.97%
5 Years-90.1%
3 Years-114.79%
Last Year-142.02%
FBIO Recent Earnings
Fortress Biotech, Inc. (FBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q4 2025Latest
Nov 14, 2025EPS
$0.11
Est $0.43
+125.6%
Revenue
$18M
Est $21M
-16.1%
Q3 2025
Aug 14, 2025EPS
$0.46
Est $0.31
-48.4%
Revenue
$16M
Est $21M
-21.9%
Q2 2025
May 21, 2025EPS
$1.03
Est $0.44
-134.1%
Revenue
$13M
Est $12M
+13.1%
Q2 2025
Mar 27, 2025EPS
$0.53
Est $0.79
+32.9%
Revenue
$15M
Est $16M
-7.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 14, 2025 | $0.11vs $0.43+125.6% | $18Mvs $21M-16.1% |
| Q3 2025 | Aug 14, 2025 | $0.46vs $0.31-48.4% | $16Mvs $21M-21.9% |
| Q2 2025 | May 21, 2025 | $1.03vs $0.44-134.1% | $13Mvs $12M+13.1% |
| Q2 2025 | Mar 27, 2025 | $0.53vs $0.79+32.9% | $15Mvs $16M-7.2% |
Based on last 12 quarters of dataView full earnings history →
FBIO Peer Comparison
Fortress Biotech, Inc. (FBIO) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XOMA | 493.33M | 41.60 | 28.49 | 83.06% | 56.4% | 31.88% | 1.57 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ROIV | 20.91B | 28.82 | -120.08 | -11.19% | -60.8% | -16.27% | 0.02 | |
 MNOV | 71.12M | 1.45 | -6.04 | -29.29% | -28.85% | 0.00 | ||
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 |
Compare FBIO vs Peers
Fortress Biotech, Inc. (FBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FBIO Income Statement
Fortress Biotech, Inc. (FBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 16.48M | 187.58M | 26.88M | 36.63M | 45.6M | 68.79M | 75.74M | 84.51M | 57.67M | 62.3M |
| Revenue Growth % | 1809.62% | 1038.25% | -85.67% | 36.26% | 24.49% | 50.86% | 10.11% | 11.58% | -31.76% | -0.32% |
| Cost of Goods Sold | 11.35M | 161.2M | 6.13M | 10.53M | 14.59M | 32.08M | 30.77M | 22.89M | 20.88M | 21.29M |
| COGS % of Revenue | 68.87% | 85.94% | 22.78% | 28.75% | 32.01% | 46.64% | 40.63% | 27.09% | 36.2% | - |
| Gross Profit | 5.13M▲ 0% | 26.38M▲ 414.2% | 20.76M▼ 21.3% | 26.1M▲ 25.7% | 31M▲ 18.8% | 36.71M▲ 18.4% | 44.97M▲ 22.5% | 61.62M▲ 37.0% | 36.8M▼ 40.3% | 41.01M▲ 0% |
| Gross Margin % | 31.13% | 14.06% | 77.22% | 71.25% | 67.99% | 53.36% | 59.37% | 72.91% | 63.8% | 65.83% |
| Gross Profit Growth % | 494.55% | 414.17% | -21.32% | 25.73% | 18.81% | 18.39% | 22.51% | 37.03% | -40.29% | - |
| Operating Expenses | 70.84M | 127.59M | 140.75M | 136.92M | 125.28M | 225.25M | 248.53M | 203.96M | 147.18M | 133.96M |
| OpEx % of Revenue | 429.86% | 68.02% | 523.6% | 373.79% | 274.73% | 327.44% | 328.13% | 241.34% | 255.18% | - |
| Selling, General & Admin | 32.91M | 73.02M | 53.37M | 55.59M | 61.17M | 86.84M | 113.66M | 90.98M | 87.73M | 108.56M |
| SG&A % of Revenue | 199.73% | 38.92% | 198.54% | 151.76% | 134.14% | 126.24% | 150.05% | 107.65% | 152.11% | - |
| Research & Development | 35.13M | 52.49M | 87.38M | 81.33M | 64.11M | 128.87M | 134.88M | 106.07M | 56.88M | 22.21M |
| R&D % of Revenue | 213.19% | 27.98% | 325.06% | 222.03% | 140.59% | 187.33% | 178.07% | 125.51% | 98.62% | - |
| Other Operating Expenses | 0 | -234K | 68K | 0 | 0 | 9.54M | 0 | 6.91M | 2.56M | 3M |
| Operating Income | -65.71M▲ 0% | -89.8M▼ 36.7% | -120M▼ 33.6% | -110.82M▲ 7.6% | -94.27M▲ 14.9% | -188.54M▼ 100.0% | -203.56M▼ 8.0% | -142.34M▲ 30.1% | -110.38M▲ 22.5% | -92.95M▲ 0% |
| Operating Margin % | -398.73% | -47.87% | -446.38% | -302.54% | -206.74% | -274.08% | -268.76% | -168.43% | -191.38% | -149.18% |
| Operating Income Growth % | -30.04% | -36.66% | -33.63% | 7.65% | 14.93% | -100% | -7.97% | 30.08% | 22.46% | - |
| EBITDA | -64.98M | -88.54M | -117.94M | -106.17M | -88.94M | -181.75M | -194.21M | -136.34M | -105.92M | -87.84M |
| EBITDA Margin % | -394.31% | -47.2% | -438.72% | -289.84% | -195.06% | -264.21% | -256.41% | -161.33% | -183.64% | -140.98% |
| EBITDA Growth % | -28.66% | -36.25% | -33.21% | 9.98% | 16.22% | -104.34% | -6.86% | 29.8% | 22.32% | 10.96% |
| D&A (Non-Cash Add-back) | 728K | 1.26M | 2.06M | 4.65M | 5.33M | 6.79M | 9.35M | 6M | 4.46M | 5.11M |
| EBIT | -67.6M | -89.83M | -120.46M | -93.13M | -93.14M | -152.96M | -203.05M | -141.72M | -108.95M | -43.88M |
| Net Interest Income | -3.39M | -6.87M | -9.24M | -9.29M | -13.81M | -14.66M | -12.24M | -9.52M | -7.24M | -7.96M |
| Interest Income | 298K | 819K | 1.1M | 2.56M | 1.52M | 649K | 1.4M | 3M | 2.68M | 2.37M |
| Interest Expense | 3.69M | 7.69M | 10.34M | 11.85M | 15.33M | 15.31M | 13.64M | 12.52M | 9.93M | 10.33M |
| Other Income/Expense | -5.58M | -7.72M | -10.8M | 9.16M | -8.58M | 24.19M | -9.9M | -11.29M | -10.16M | 39.48M |
| Pretax Income | -71.29M▲ 0% | -98.32M▼ 37.9% | -130.8M▼ 33.0% | -101.66M▲ 22.3% | -102.85M▼ 1.2% | -164.35M▼ 59.8% | -213.46M▼ 29.9% | -153.63M▲ 28.0% | -120.54M▲ 21.5% | -53.47M▲ 0% |
| Pretax Margin % | -432.58% | -52.42% | -486.57% | -277.54% | -225.55% | -238.92% | -281.83% | -181.79% | -209% | -85.82% |
| Income Tax | 0 | 1.51M | -463K | 0 | 136K | 473K | 449K | 521K | 312K | 362K |
| Effective Tax Rate % | 0% | -1.54% | 0.35% | 0% | -0.13% | -0.29% | -0.21% | -0.34% | -0.26% | -0.68% |
| Net Income | -55.09M▲ 0% | -66.88M▼ 21.4% | -84.15M▼ 25.8% | -39.96M▲ 52.5% | -46.53M▼ 16.4% | -64.7M▼ 39.1% | -86.58M▼ 33.8% | -60.64M▲ 30.0% | -46M▲ 24.1% | 3.99M▲ 0% |
| Net Margin % | -334.31% | -35.65% | -313.02% | -109.09% | -102.03% | -94.06% | -114.3% | -71.75% | -79.75% | 6.4% |
| Net Income Growth % | -13.77% | -21.38% | -25.83% | 52.51% | -16.43% | -39.07% | -33.8% | 29.96% | 24.14% | 108.22% |
| Net Income (Continuing) | -71.29M | -97.51M | -130.8M | -101.66M | -102.98M | -164.83M | -213.91M | -154.15M | -120.86M | -53.83M |
| Discontinued Operations | 0 | 0 | -11.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 44.47M | 67.93M | 17.89M | 46.32M | 96.66M | 117.2M | 8.3M | -20.96M | -24.38M | 9.32M |
| EPS (Diluted) | -20.68▲ 0% | -24.08▼ 16.4% | -29.04▼ 20.6% | -10.95▲ 62.3% | -9.75▲ 11.0% | -11.85▼ 21.5% | -14.55▼ 22.8% | -8.47▲ 41.8% | -2.69▲ 68.2% | 0.12▲ 0% |
| EPS Growth % | -11.42% | -16.44% | -20.6% | 62.29% | 10.96% | -21.54% | -22.78% | 41.79% | 68.24% | 92.18% |
| EPS (Basic) | -20.68 | -24.08 | -29.04 | -10.95 | -9.75 | -11.85 | -14.55 | -8.47 | -2.69 | - |
| Diluted Shares Outstanding | 2.66M | 2.78M | 2.9M | 3.65M | 4.8M | 5.45M | 5.92M | 8.11M | 20.78M | 33.1M |
| Basic Shares Outstanding | 2.66M | 2.78M | 2.9M | 3.65M | 4.8M | 5.45M | 5.92M | 8.11M | 20.78M | 27.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FBIO Balance Sheet
Fortress Biotech, Inc. (FBIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 109.63M | 183.18M | 111.21M | 156.25M | 266.15M | 346.46M | 230.43M | 117.02M | 90.37M | 118.5M |
| Cash & Short-Term Investments | 91.68M | 130.95M | 83.11M | 136.86M | 233.35M | 305.74M | 178.27M | 80.93M | 57.26M | 86.22M |
| Cash Only | 88.29M | 113.92M | 65.51M | 136.86M | 233.35M | 305.74M | 178.27M | 80.93M | 57.26M | 86.22M |
| Short-Term Investments | 3.39M | 39.03M | 17.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 5.19M | 15.15M | 5.5M | 14.4M | 24.67M | 23.79M | 28.35M | 15.39M | 10.4M | 18.13M |
| Days Sales Outstanding | 114.88 | 29.48 | 74.65 | 143.53 | 197.49 | 126.23 | 136.6 | 66.46 | 65.83 | 92.36 |
| Inventory | 203K | 171K | 678K | 857K | 1.4M | 9.86M | 14.16M | 10.21M | 14.43M | 11.82M |
| Days Inventory Outstanding | 6.53 | 0.39 | 40.4 | 29.7 | 35.11 | 112.19 | 167.93 | 162.72 | 252.28 | 221.16 |
| Other Current Assets | 0 | 38.57M | 15.18M | 0 | 6.72M | 0 | 9.66M | 10.5M | 8.28M | 2.34M |
| Total Non-Current Assets | 61.1M | 62.77M | 29.79M | 70.17M | 67.26M | 50.04M | 63.87M | 50.5M | 53.85M | 62.9M |
| Property, Plant & Equipment | 7.38M | 9.51M | 12.02M | 33.91M | 32.41M | 34.07M | 33.01M | 23.5M | 17.12M | 14.93M |
| Fixed Asset Turnover | 2.23x | 19.72x | 2.24x | 1.08x | 1.41x | 2.02x | 2.29x | 3.60x | 3.37x | 3.91x |
| Goodwill | 18.64M | 18.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 17.41M | 15.22M | 1.42M | 7.38M | 14.63M | 12.55M | 27.2M | 20.29M | 31.86M | 28.67M |
| Long-Term Investments | 1.41M | 1.39M | 0 | 11.15M | 19.21M | 2.22M | 2.69M | 2.44M | 1.55M | 2.77M |
| Other Non-Current Assets | 16.25M | 18M | 16.35M | 17.73M | 1.01M | 3.42M | 3.66M | 4.28M | 3.32M | 29.91M |
| Total Assets | 170.73M▲ 0% | 245.95M▲ 44.1% | 140.99M▼ 42.7% | 226.42M▲ 60.6% | 333.41M▲ 47.3% | 396.5M▲ 18.9% | 294.3M▼ 25.8% | 167.53M▼ 43.1% | 144.22M▼ 13.9% | 181.41M▲ 0% |
| Asset Turnover | 0.10x | 0.76x | 0.19x | 0.16x | 0.14x | 0.17x | 0.26x | 0.50x | 0.40x | 0.38x |
| Asset Growth % | 43.94% | 44.06% | -42.67% | 60.59% | 47.25% | 18.92% | -25.78% | -43.08% | -13.91% | 46.74% |
| Total Current Liabilities | 56.56M | 71.44M | 55.61M | 45.62M | 51.76M | 101.04M | 127.72M | 84.91M | 71.4M | 54.07M |
| Accounts Payable | 14.21M | 10M | 17.86M | 10.05M | 11.41M | 47.43M | 57.24M | 34.81M | 31.64M | 18.77M |
| Days Payables Outstanding | 457.11 | 22.65 | 1.06K | 348.37 | 285.42 | 539.57 | 678.93 | 555 | 553.05 | 421.83 |
| Short-Term Debt | 2.03M | 13.23M | 19.08M | 7.22M | 6.37M | 5.32M | 10.18M | 9.45M | 625K | 5.63M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 2.61M | 728K | 0 | 0 | 0 |
| Other Current Liabilities | 24.54M | 42.14M | 1.29M | 27K | 27.14M | 34.42M | 46.62M | 31.27M | 4.84M | 2.54M |
| Current Ratio | 1.94x | 2.56x | 2.00x | 3.43x | 5.14x | 3.43x | 1.80x | 1.38x | 1.27x | 1.27x |
| Quick Ratio | 1.93x | 2.56x | 1.99x | 3.41x | 5.11x | 3.33x | 1.69x | 1.26x | 1.06x | 1.06x |
| Cash Conversion Cycle | -335.7 | 7.22 | -949.02 | -175.13 | -52.81 | -301.15 | -374.4 | -325.82 | -234.94 | -108.31 |
| Total Non-Current Liabilities | 31.2M | 54.01M | 65.64M | 108.27M | 84.65M | 69.58M | 116.56M | 81.03M | 74.47M | 62.16M |
| Long-Term Debt | 26.18M | 49.27M | 60.42M | 82.43M | 59.81M | 46.56M | 93.14M | 60.86M | 57.96M | 47.77M |
| Capital Lease Obligations | 0 | 0 | 0 | 23.71M | 22.89M | 20.99M | 21.57M | 18.28M | 14.75M | 54.64M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.01M | 4.74M | 5.21M | 2.14M | 1.95M | 2.03M | 1.85M | 1.89M | 1.76M | 6.74M |
| Total Liabilities | 87.76M | 125.45M | 121.25M | 153.89M | 136.41M | 170.63M | 244.28M | 165.94M | 145.87M | 116.22M |
| Total Debt | 28.21M | 62.5M | 79.5M | 115.14M | 89.08M | 74.98M | 127.34M | 88.59M | 75.96M | 68.29M |
| Net Debt | -60.08M | -47.41M | 13.99M | -21.72M | -144.28M | -230.77M | -50.92M | 7.67M | 18.7M | -17.93M |
| Debt / Equity | 0.34x | 0.52x | 4.03x | 1.59x | 0.45x | 0.33x | 2.55x | 55.82x | - | 1.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.78x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.20x |
| Interest Coverage | -17.81x | -11.68x | -11.61x | -9.35x | -6.15x | -12.32x | -14.92x | -11.37x | -11.12x | -4.25x |
| Total Equity | 82.97M▲ 0% | 120.5M▲ 45.2% | 19.74M▼ 83.6% | 72.53M▲ 267.4% | 197M▲ 171.6% | 225.88M▲ 14.7% | 50.02M▼ 77.9% | 1.59M▼ 96.8% | -1.64M▼ 203.6% | 65.19M▲ 0% |
| Equity Growth % | -1.55% | 45.24% | -83.62% | 267.38% | 171.6% | 14.66% | -77.85% | -96.83% | -203.59% | 1689.37% |
| Book Value per Share | 31.14 | 43.39 | 6.81 | 19.89 | 41.04 | 41.47 | 8.44 | 0.20 | -0.08 | 1.97 |
| Total Shareholders' Equity | 38.49M | 52.57M | 1.85M | 26.21M | 100.34M | 108.67M | 41.72M | 22.54M | 22.74M | 55.86M |
| Common Stock | 49K | 551K | 717K | 574K | 95K | 101K | 110K | 15K | 28K | 31K |
| Retained Earnings | -245.25M | -312.13M | -396.27M | -436.23M | -482.76M | -547.46M | -634.23M | -694.87M | -740.87M | -730.12M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -481K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 44.47M | 67.93M | 17.89M | 46.32M | 96.66M | 117.2M | 8.3M | -20.96M | -24.38M | 9.32M |
FBIO Cash Flow Statement
Fortress Biotech, Inc. (FBIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -45.81M | -85.43M | -98.85M | -94.96M | -83.68M | -116.54M | -179.4M | -128.22M | -80.19M | -80.19M |
| Operating CF Margin % | -277.99% | -45.54% | -367.71% | -259.25% | -183.52% | -169.41% | -236.85% | -151.72% | -139.04% | - |
| Operating CF Growth % | -124.82% | -86.48% | -15.71% | 3.93% | 11.88% | -39.27% | -53.94% | 28.53% | 37.46% | 129.33% |
| Net Income | -71.29M | -99.84M | -130.8M | -101.66M | -102.98M | -164.83M | -213.91M | -154.15M | -120.86M | 3.99M |
| Depreciation & Amortization | 1.13M | 3.35M | 2.06M | 4.65M | 5.33M | 6.79M | 9.35M | 6M | 4.46M | 2.75M |
| Stock-Based Compensation | 12.13M | 14.01M | 15.01M | 13.19M | 13.45M | 19.49M | 22.99M | 17.03M | 32.62M | 42.47M |
| Deferred Taxes | -73K | -8.56M | 287K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 10.32M | 7.84M | 8.86M | -6.3M | 5.31M | -14.36M | 2.89M | 15.42M | 11.71M | -37.5M |
| Working Capital Changes | 1.97M | -2.23M | 5.74M | -4.84M | -4.78M | 36.37M | -715K | -12.52M | -8.13M | -20.02M |
| Change in Receivables | -1.83M | -5.93M | 2.26M | -6.91M | -10.32M | 834K | -4.84M | 12.52M | 4.47M | -6.8M |
| Change in Inventory | -203K | 32K | -507K | -179K | -547K | -8.46M | 1.74M | 3.95M | -4.22M | -30K |
| Change in Payables | 5.39M | 9.9M | 4.66M | 1.95M | 11.1M | 43.31M | 8.35M | -24.38M | -6.39M | -9.92M |
| Cash from Investing | -6.06M | -41.63M | 18.82M | 20.1M | -7.16M | 40.51M | -22.93M | -2.1M | -15M | -4.88M |
| Capital Expenditures | -6.37M | -5.45M | -9.36M | -2.35M | -1.93M | -4.57M | -2.71M | -63K | -15M | 0 |
| CapEx % of Revenue | 38.65% | 2.9% | 34.8% | 6.4% | 4.22% | 6.64% | 3.58% | 0.07% | 26.01% | - |
| Acquisitions | 4.45M | -19K | 2.27M | -1.2M | 0 | 56.86M | -20M | 0 | 0 | 2.87M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -4.14M | -163K | 7.51M | 6.04M | -5.24M | -11.78M | -213K | -2.04M | 0 | -7.75M |
| Cash from Financing | 42.91M | 150.38M | 50.65M | 146.71M | 172.41M | 148.99M | 75.32M | 32.74M | 70.64M | 97.54M |
| Debt Issued (Net) | 6.14M | 37.16M | 17.3M | 15M | -29.67M | -9.64M | 49.25M | -38.79M | -7.33M | -1.26M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | -299K | -2.34M | -2.56M | -6.75M | -8.78M | -8.78M | -8.77M | -4.71M | -664K |
| Share Repurchases | 0 | 0 | 0 | 0 | -70K | 0 | -1.11M | 0 | 0 | 0 |
| Other Financing | -594K | -6.6M | -2.73M | -9.96M | -8.78M | -4.8M | -6.74M | -529K | -163K | 2.32M |
| Net Change in Cash | -9.89M▲ 0% | 27.15M▲ 374.6% | -29.38M▼ 208.2% | 71.85M▲ 344.6% | 81.56M▲ 13.5% | 72.97M▼ 10.5% | -127.01M▼ 274.1% | -97.59M▲ 23.2% | -24.55M▲ 74.8% | 26.52M▲ 0% |
| Free Cash Flow | -56.32M▲ 0% | -90.88M▼ 61.4% | -108.2M▼ 19.1% | -104.36M▲ 3.6% | -90.85M▲ 12.9% | -132.89M▼ 46.3% | -182.46M▼ 37.3% | -136.32M▲ 25.3% | -95.19M▲ 30.2% | -66.14M▲ 0% |
| FCF Margin % | -341.74% | -48.45% | -402.51% | -284.9% | -199.23% | -193.17% | -240.89% | -161.3% | -165.05% | -106.16% |
| FCF Growth % | -74.04% | -61.36% | -19.07% | 3.56% | 12.95% | -46.28% | -37.3% | 25.28% | 30.17% | 35.34% |
| FCF per Share | -21.14 | -32.72 | -37.35 | -28.61 | -18.93 | -24.40 | -30.79 | -16.81 | -4.58 | -4.58 |
| FCF Conversion (FCF/Net Income) | 0.83x | 1.28x | 1.17x | 2.38x | 1.80x | 1.80x | 2.07x | 2.11x | 1.74x | -16.59x |
| Interest Paid | 400K | 778K | 0 | 5.9M | 8.82M | 6.92M | 9.42M | 7.95M | 7.16M | 4.11M |
| Taxes Paid | 104K | 4.24M | 0 | 0 | 0 | 993K | 858K | 0 | 120K | 5K |
FBIO Key Ratios
Fortress Biotech, Inc. (FBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -65.89% | -65.74% | -120% | -86.61% | -34.52% | -30.6% | -62.76% | -234.97% | - | 6.12% |
| Return on Invested Capital (ROIC) | -306.54% | -146.45% | -175.05% | -196.59% | -136.57% | -591.24% | - | -2555.51% | -629.42% | -629.42% |
| Gross Margin | 31.13% | 14.06% | 77.22% | 71.25% | 67.99% | 53.36% | 59.37% | 72.91% | 63.8% | 65.83% |
| Net Margin | -334.31% | -35.65% | -313.02% | -109.09% | -102.03% | -94.06% | -114.3% | -71.75% | -79.75% | 6.4% |
| Debt / Equity | 0.34x | 0.52x | 4.03x | 1.59x | 0.45x | 0.33x | 2.55x | 55.82x | - | 1.05x |
| Interest Coverage | -17.81x | -11.68x | -11.61x | -9.35x | -6.15x | -12.32x | -14.92x | -11.37x | -11.12x | -4.25x |
| FCF Conversion | 0.83x | 1.28x | 1.17x | 2.38x | 1.80x | 1.80x | 2.07x | 2.11x | 1.74x | -16.59x |
| Revenue Growth | 1809.62% | 1038.25% | -85.67% | 36.26% | 24.49% | 50.86% | 10.11% | 11.58% | -31.76% | -0.32% |
FBIO Frequently Asked Questions
Fortress Biotech, Inc. (FBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fortress Biotech, Inc. (FBIO) reported $62.3M in revenue for fiscal year 2024.
Fortress Biotech, Inc. (FBIO) saw revenue decline by 31.8% over the past year.
Yes, Fortress Biotech, Inc. (FBIO) is profitable, generating $4.0M in net income for fiscal year 2024 (-79.8% net margin).
Dividend & Returns
Yes, Fortress Biotech, Inc. (FBIO) pays a dividend with a yield of 1.31%. This makes it attractive for income-focused investors.
Fortress Biotech, Inc. (FBIO) had negative free cash flow of $66.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More FBIO
Fortress Biotech, Inc. (FBIO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates